Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CAR-T Reimbursement Threatened By Medicare Coverage Analysis, Manufacturers Say

Executive Summary

Novartis, Gilead/Kite and Celgene protest the US Centers for Medicare and Medicaid Services’ decision to launch a Medicare coverage analysis for CAR-T drugs because it might lead to coverage restrictions.

You may also be interested in...



Medicare Advisers Endorse Patient Reported Outcomes For CAR-T With Caveats

Medicare Evidence Development and Coverage Advisory Committee votes that four existing tools are valid and could be “generalizable” to Medicare beneficiaries.

CAR-T Drugs' Patient-Reported Outcomes To Be Focus Of MedCAC Meeting

Focus is in line with past US Medicare advisory panel meetings on other diseases.

CAR-T Drugs' Patient-Reported Outcomes To Be Focus Of MedCAC Meeting

Focus is in line with past US Medicare advisory panel meetings on other diseases.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS123335

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel